Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $112 and keeps an Underweight rating on the shares. The firm adjusted the company’s model into the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Notable companies reporting before tomorrow’s open
- ZBH Upcoming Earnings Report: What to Expect?
- Zimmer Biomet: FDA grants BDD for iodine-treated total hip replacement system
- Zimmer Biomet: FDA grants BDD for treated total hip replacement system
- Zimmer Biomet’s Knee System Study: A Potential Game-Changer in Orthopedics